

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Liver cancer	Transmembrane 4 L six family member 5 (TM4SF5)	<p>Studies in patient samples, cell culture and mice suggest antagonizing TM4SF5 could help treat hepatocellular carcinoma (HCC). In patient samples, HCC expressed TM4SF5, whereas normal liver tissue did not. In a human liver cell line expressing TM4SF5, an anti-TM4SF5 mAb inhibited cell migration and suppressed cell growth compared with IgG control or vehicle. In xenograft and syngeneic mouse models of HCC, i.p. injection of the mAb decreased tumor progression compared with IgG control injection. Next steps could include evaluating different isotypes of the anti-TM4SF5 mAb in additional preclinical studies.</p> <p>SciBX 7(24); doi:10.1038/scibx.2014.705 Published online June 19, 2014</p>	Patent and licensing status unavailable	<p>Kwon, S. <i>et al. Cancer Res.</i>; published online May 6, 2014; doi:10.1158/0008-5472.CAN-13-2730 Contact: Younghee Lee, Chungbuk National University, Chungcheongbuk-do, South Korea e-mail: yhl4177@cbnu.ac.kr</p>